Ursodeoxycholic acid dose‐dependently improves liver injury in rats fed a methionine‐ and choline‐deficient diet

Abstract

The present data demonstrate a beneficial effect of UDCA that manifested by the decrease of liver steatosis, inflammatory signs and serum tumor necrosis factor-α content especially of the highest 40 and 80 mg/kg day doses.

Beneficial effects of combined ursodeoxycholic acid and angiotensin-II type 1 receptor blocker on hepatic fibrogenesis in a rat model of nonalcoholic steatohepatitis

“…We previously found that treatment with clinically equivalent doses of either UDCA (100 mg/kg/day) or ARB (30 mg/kg/day) successfully ameliorated hepatic fibrosis induced by an 8 week CDAA diet in addition to suppressing Ac-HSCs. dose of 80 mg/kg/day for 4 weeks significantly attenuated hepatic steatosis and inflammation, but failed to slow the progression of liver fibrosis during the development of NASH [25], a finding more similar to results of clinical trials. This discrepancy in results is likely attributable to the doses of UDCA administered and the time at which UDCA treatment was initiated.…”

Is nonalcoholic fatty liver disease an endogenous alcoholic fatty liver disease? – A mechanistic hypothesis

“…It is known that NAFLD and alcoholic fatty liver disease (AFLD) share similar histopathological and molecular biological features, as well as identical polymorphism in the patatin-like phospholipase domain-containing 3 gene (PNPLA3) [3][4][5]. Besides, the finding that patients with nonalcoholic steatohepatitis (NASH) produce more endogenous ethanol (EE) than control subjects further strengthens this connection [6][7][8][9]. As a result, it is suspected that NAFLD and AFLD have a common mechanistic background [3].…”

Ursodeoxycholic acid alleviates cholestasis-induced histophysiological alterations in the male reproductive system of bile duct-ligated rats

“…It is the most widely used therapeutic agent for treating cholestatic liver diseases, and is the only FDA-approved drug to treat primary biliary cirrhosis [4]. UDCA is also used to ameliorate other hepatopathies [5][6][7], and even extrahepatic ones [8][9][10][11][12]. Experimental and clinical data suggests several mechanisms of action for the therapeutic effects of UDCA in cholestatic disorders.…”